What's new? {#FPar1}
===========

In contemporary real-world practice, wide ranges of demography, severity of heart failure and comorbidities of HFrEF patients were observed between heart failure clinics in the Netherlands.The prescription rates and prescribed dosages of guideline-recommended heart failure medication differed significantly between centres, not fully explained by differences in patient profiles.In HFmrEF patients, overall use and doses of heart failure medication, and ranges between centres did not differ considerably from those in HFrEF.Practical recommendations to improve heart failure management in transmural networks are provided.

Introduction {#Sec1}
============

Heart failure (HF) is associated with a high symptom burden, morbidity and mortality \[[@CR1]--[@CR3]\]. Optimising guideline-recommended HF therapies improve health-related quality of life and prognosis \[[@CR4]--[@CR6]\]. However, in real-world practice, implementation and adherence to recommended treatment, a benchmark of quality of care, are suboptimal. A recent analysis of medication profiles of 22,476 unselected patients with a diagnosis of HF at hospital discharge between 2001 and 2015 derived from the Dutch PHARMO Database Network showed only partial improvement of prescribed HF medication over time \[[@CR7]\]. The percentage of patients prescribed the combination of a beta blocker and an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin receptor blocker increased from 24 to approximately 45% within this 15-year period. The percentage of patients who also used a mineralocorticoid receptor antagonist (MRA) reached approximately 20%. Notably, the probability of being prescribed these combinations decreased with increasing age and there was no significant increase in MRA prescriptions. Moreover, recent real-world registries demonstrated underuse of HF therapies despite clear evidence-based recommendations \[[@CR8]--[@CR10]\].

In fact, randomised clinical trials and surveys did not represent real-life HF populations \[[@CR11]--[@CR13]\]. Moreover, the distribution of recommended HF treatment and considerable practice variation between regions and hospitals are largely unexplained, but also unexplored.

In a large-scale real-world registry at Dutch HF outpatient clinics, we therefore investigated the differences in medical HF therapies and determinants of prescription of individual, recommended HF drugs in HFrEF patients \[[@CR14], [@CR15]\] among 34 HF clinics in the Netherlands.

Methods {#Sec2}
=======

The design and methods of the CHECK-HF (*C*hronic *H*eart failure *E*SC guideline-based *C*ardiology practice Quality project) registry have been published in detail earlier \[[@CR14]\]. Briefly, the CHECK-HF registry consists of 10,910 patients with chronic HF from a total of 34 participating centres (40% of the 86 centres in the Netherlands of which 60 have an outpatient HF unit) (Fig. [1](#Fig1){ref-type="fig"}). Patients were included cross-sectionally based on the available records of these patients. Between 2013 and 2016, all participating centres included patients diagnosed with HF based on the 2012 ESC guidelines on HF (i.e. based on symptoms and echo parameters) who were seen at the outpatient HF clinic (96%) or general cardiology outpatient clinic (4%) if no specific HF clinic was present.Fig. 1Geographical distribution of the 34 participating clinics of the CHECK-HF registry in the Netherlands

Baseline patient characteristics, aetiology of HF, comorbidities, basic echocardiographic and electrocardiographic (ECG) parameters, laboratory markers, pacemaker, implantable cardioverter-defibrillator treatment and cardiac resynchronisation therapy as well as prescription rates of medication (drug name, dosage and frequency and total daily dose) were recorded. The target doses of guideline-recommended HF medication are presented in Suppl. Table 1. Drug doses were calculated compared with the recommended dose and according to guidelines as a daily dose or %, percentage of actual recommended daily dose.

Furthermore, contraindications and intolerance as indicated by the treating physician were collected. No predefined rules were applied to determine absolute contraindications.

In 283 (2.6%) patients, recording of ejection fraction in the database was insufficient to classify patients, so these patients were excluded from this analysis.

Based on echocardiographic results, the remaining 10,627 patients were divided based on left ventricular ejection fraction (LVEF) or visual assessment of the function of the left ventricle into HF with preserved ejection fraction (HFpEF) (LVEF ≥50%, *n* = 2,267 (21%)) and HF with reduced ejection fraction (HFrEF: LVEF \<50%, *n* = 8,360 (79%)), according to the 2012 ESC HF guidelines \[[@CR4]\].

For a sub-analysis according to the newer 2016 ESC HF guidelines, patients with an assessed LVEF \<50% were categorised into HF with mid-range ejection fraction (HFmrEF) (LVEF 40--49%, *n* = 1,574 (19%)), HFrEF (LVEF \<40%, *n* = 5,701 (68%)), and into HF with a semi-quantitative analysis of the systolic left ventricular function only (*n* = 1,085 (13%)). In the current analyses, we focused on the prescribed HF medication in HFrEF patients (LVEF \<50%).

The Medical Research Ethics Committee of the Maastricht University Medical Center, the Netherlands, provided ethical approval for anonymously analysing existing patient data. No informed consent of the participants in this registry was required.

Statistics {#Sec3}
----------

Continuous data are expressed as mean value ± standard deviation (SD) or median and interquartile range, depending on the distribution of the data, and compared by applying one-way analysis of variances (ANOVA) or Mann-Whitney U test as appropriate. Categorical data are expressed as counts and percentages, and compared by the Pearson chi-squared test. A two-sided *p*-value of 0.05 was considered statistically significant. Multivariable predictors for the use of HF medication associated with the hospital-ranked prescription of HF medication (beta blocker, renin-angiotensin system \[RAS\] inhibitor, MRA, ivabradine and diuretics, respectively) were sought, using multivariable logistic regression analysis, using the stepwise forward procedure. All predictors of medication use in univariable analysis at a *p*-value of \<0.10 were included in the multivariable regression analysis. Results of logistic regression are presented as odds ratios (ORs) and confidence intervals (CIs).

All analyses were performed with SPSS Statistical Package version 25.0 (SPSS Inc, Chicago, Illinois).

Results {#Sec4}
=======

Baseline characteristics of the total group of 8,360 HFrEF patients are shown in Table [1](#Tab1){ref-type="table"}. Mean age was 72.3 ± 11.8 years (ranging between 69.1 ± 11.9 and 76.6 ± 10.0 between the clinics), 63.9% were men (ranging between 54.3 and 78.1%), 27.3% were in New York Heart Association (NYHA) class III/IV (ranging between 8.8 and 62.1%) and the average estimated glomerular filtration rate (eGFR) was 59.6 ± 24.6 ml/min (ranging between 45.7 ± 23.5 and 97.1 ± 16.5). Between centres, a wide range of prevalence rates with regard to ischaemic aetiology of HF, atrial fibrillation and comorbidities were found, as presented in Table [1](#Tab1){ref-type="table"}. When subdividing HF patients in LVEF groups according to ESC guidelines 2016, HFmrEF patients (*n* = 1,574) were more often female, had less often ischaemic aetiology, less wide QRS complex and more often atrial fibrillation, hypertension and chronic obstructive pulmonary disease (COPD), all compared with HFrEF patients (*n* = 5,701). However, in both groups, there was a wide variation of all baseline characteristics between centres (Suppl. Tables 2 and 3).Table 1Baseline characteristics of HFrEF patients (LVEF \<50%) and range between centresOverall populationRangeNumber of patients8,360 32; 1,549Age (years) (*n* = 8,351)   72.27 ± 11.8 69.1 ± 11.9;  76.6 ± 10.0Male gender (*n* = 8,323)5,320 (63.9) 54.3; 78.1BMI, kg/m2 (*n* = 7,671)   27.2 ± 5.2 26.2 ± 4.7;  28.4 ± 5.1*NYHA* (*n* = 8,262)-- I1,313 (15.9)  0.0; 45.5-- II4,692 (56.8) 35.0; 88.1-- III2,108 (25.5)  8.8; 60.0-- IV  149 (1.8)  0.0; 9.6LVEF, % (*n* = 6,179)   32.6 ± 10.5 28.4 ± 10.5;  44.2 ± 16.0*Cause of HF* (*n* = 8,094)-- Ischaemic cause of HF4,182 (51.7) 34.9;  63.4-- Non-ischaemic cause of HF3,912 (48.3) 36.6;  65.1Systolic BP, mm Hg (*n* = 8,246)  125.7 ± 20.7113.8 ± 19.6; 135.4 ± 22.7Diastolic BP, mm Hg (*n* = 8,252)   71.2 ± 11.4 64.9 ± 10.4;  75.1 ± 12.9Heart rate, bpm (*n* = 8,248)   72.0 ± 13.9 64.7 ± 8.0;  76.7 ± 17.1Atrial fibrillation (*n* = 8,253)2,109 (25.6) 12.2;  50.0LBBB (*n* = 8,360)1,414 (16.9)  0.0;  30.2QRS ≥130 ms (*n* = 6,936)2,774 (40.0)  0.0;  53.5eGFR (*n* = 5,883)   59.6 ± 24.6 45.7 ± 23.5;  97.1 ± 16.5*eGFR* (*n* = 5,883)-- \<30  667 (11.3)  0.0;  27.3-- 30--592,442 (41.5)  0.0;  54.5-- ≥602,774 (47.2) 18.2; 100.0*Comorbidity* (*n* = 7,488)-- Hypertension2,978 (39.8)  7.8;  75.5-- Diabetes Mellitus2,174 (29.0) 16.7;  51.0-- COPD1,381 (18.4)  9.5;  29.9-- OSAS  495 (6.6)  0.0;  14.1-- Thyroid disease  557 (7.4)  0.6;  11.8-- Renal insufficiency^a^3,950 (56.3) 30.5;  78.9-- No relevant comorbidity  855 (13.6)  0.0;  28.3^a^Defined as eGFR \<60 ml/min or a history of renal failure*BMI* body mass index, *NYHA* New York Heart Association classification, *LVEF* left ventricular ejection fraction, *HF* heart failure, *HFrEF* HF with reduced ejection fraction, *HFmrEF* HF with mid-range ejection fraction, *HFpEF* HF with preserved ejection fraction, *BP* blood pressure, *LBBB* left bundle branch block, *eGFR* estimated glomerular filtration rate, *NT-proBNP N*-terminal pro-brain natriuretic peptide, *COPD* chronic obstructive pulmonary disease, *OSAS* obstructive sleep apnoea syndrome

Guideline-recommended medical therapy in HFrEF {#Sec5}
----------------------------------------------

The prescription rates ranged between centres from 58.9--97.4% for beta blocker according to ESC guidelines 2012 (*p* \< 0.01), 61.9--97.1% for renin-angiotensin system (RAS) inhibitors (*p* \< 0.01), 29.9--86.8% for MRA (*p* \< 0.01), 0.0--31.3% for ivabradine (*p* \< 0.01) and 64.9--100.0% for diuretics (*p* \< 0.01), see Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. In symptomatic HF patients (NYHA class II--IV), guideline-recommended medication only slightly differed from the total HFrEF group (Suppl. Table 4).Table 2Prescription rates of HF medication according to ESC Guidelines 2012 versus 2016 per participating clinic (*n* = 34)Guideline-recommended pharmacotherapy (average % (min.--max.))Beta blockerRAS inhibitorMRAIvabradineDiureticsESC Guidelines 2012HFrEF80.1 (58.9--97.4)81.2 (61.9--97.1)53.0 (29.9--86.8)4.6 (0.0--31.3)82.8(64.9--100.0)ESC Guidelines 2016HFrEF81.0 (63.6--96.0)83.2 (65.3--97.4)56.4 (34.1--88.0)5.4 (0.0--31.0)83.4 (65.4--100.0)HFmrEF77.7 (30.8--100.0)76.8 (33.3--100.0)45.1 (22.2--100.0)3.1 (0.0--33.3)79.5 (58.3--100.0)HFsemiq78.6 (0.0--100.0)77.6 (0.0--100.0)46.3(0.0--100.0)2.5 (0.0--30.8)84.8 (0.0--100.0)*HF* heart failure, *HFrEF* HF with reduced ejection fraction, *HFmrEF* HF with mid-range ejection fraction, *HFsemiq* HF with semiquantitatively estimated left ventricular ejection fraction---though \<50%, *ESC* European Society of Cardiology, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonistsFig. 2Prescription rates and prescribed dosages of HF medication in HFrEF patients (LVEF \<50%) per participating clinic (*n* = 34) (*The left panels* show the order of hospitals on the x‑axis based on the percentage of prescription rate of each drug. *The red bar* is the overall presciption rate (%) and *the green bars* are the prescription rates (%) in each clinic. The same order is shown in *the panels on the right*.) (*HF* heart failure, *HFrEF* heart failure with reduced ejection fraction, *LVEF* left ventricular ejection fraction, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonists)

Dual therapy (beta blocker and RAS inhibitor) was prescribed in average 66.3% (min. 47.7 to max. 80.5) of HFrEF patients, one out of two in 28.7% (15.6--43.7) and none in 5.0% (0.9--13.5) respectively. Triple therapy (beta blocker, RAS inhibitor and MRA) was prescribed in average 35.6% (16.1--68.4) of HFrEF patients, two out of three in 45.7% (28.9--58.9), one out of three in 16.1% (0.0--24.7) and none in 2.6% (0.0--6.9) respectively. Also, the percentage of patients who received the target dose differed significantly, 5.9--29.1% for beta blocker (*p* \< 0.01), 18.4--56.1% for RAS inhibitor (*p* \< 0.01) and 13.2--60.6% for MRA (*p* \< 0.01).

HFrEF patients seen at HF clinics received more often beta blockers, MRA, ivabradine and diuretics in comparison with those seen in general cardiology outpatient clinics, although rates of prescribed of RAS inhibitors were similar (Suppl. Table 5). Women with HFrEF less often received RAS inhibitors (79% vs 83%), but more often beta blockers (82% vs 79%) as compared with men. MRA were given in 53% of patients, both men and women (Suppl. Table 6).

Multivariable analysis of hospitals showed that the differences in prescribed HF medication between centres cannot be explained by clinical variables (Table [3](#Tab3){ref-type="table"}, see Suppl. Table 7 for univariable analysis).Table 3Multivariable analysis of hospital differences in medical treatment of HFrEF patients (LVEF \<50%)Beta blockerRAS inhibitorMRAIvabradineDiureticsOR \[95% CI\]OR \[95% CI\]OR \[95% CI\]OR \[95% CI\]OR \[95% CI\]UnivariableHospital1.05 \[1.04--1.05\]1.04 \[1.04--1.04\]1.06 \[1.06--1.06\]1.09 \[1.08--1.10\]1.06 \[1.06--1.06\]MultivariableHospital1.05 \[1.04--1.06\]1.05 \[1.04--1.06\]1.06 \[1.05--1.07\]1.09 \[1.07--1.10\]1.04 \[1.03--1.05\]Gender1.20 \[1.02--1.40\]------1.31 \[1.06--1.61\]Age (per 10 years)0.83 \[0.78--0.89\]0.79 \[0.72--0.87\]0.87 \[0.83--0.91\]0.61 \[0.56--0.67\]1.14 \[1.04--1.25\]BMI--1.04 \[1.02--1.06\]1.02 \[1.01--1.03\]--1.06 \[1.04--1.08\]Systolic BP (per 10 mm Hg)----0.84 \[0.82--0.87\]--0.93 \[0.87--1.00\]Diastolic BP (per 10 mm Hg)------0.88 \[0.79--0.98\]0.89 \[0.80--1.00\]NYHA classification--0.72 \[0.63--0.82\]1.17 \[1.08--1.27\]1.26 \[1.05--1.50\]1.53 \[1.30--1.80\]Heart rate (per 10 beats/min)--0.84 \[0.79--0.89\]----1.12 \[1.04--1.21\]QRS duration (per 10 ms)--0.97 \[0.95--0.99\]1.04 \[1.02--1.05\]--1.32 \[1.01--1.72\]eGFR (per 10 ml/min)--1.06 \[1.01--1.11\]----Ischaemic aetiology--0.76 \[0.60--0.97\]----Hypertension1.22 \[1.05--1.42\]------Diabetes mellitus II------1.58 \[1.21--2.08\]1.42 \[1.11--1.81\]COPD------1.58 \[1.21--2.08\]1.32 \[1.01--1.72\]Renal insufficiency^a^--------2.50 \[2.03--3.09\]-- variable not included in the model*LVEF* left ventricular ejection fraction, *HF* heart failure, *HFrEF* HF with reduced ejection fraction, *OR* odds ratio, *CI* confidence interval, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonists, *BMI* body mass index, *NYHA* New York Heart Association, *BP* blood pressure, *eGFR* estimated glomerular filtration rate, *COPD* chronic obstructive pulmonary disease^a^Defined as eGFR \<60 ml/min or a history of renal failure

According to ESC guidelines 2016, the prescription rates in HF patients with LVEF \<40%, both overall and ranges between centres of prescription rates of HF medication, were not different in a clinically meaningful way from HF with LVEF \<50%.

Medical treatment of HFmrEF and semi-quantitative patients {#Sec6}
----------------------------------------------------------

The distribution of beta blockers, RAS inhibitors and MRA in HFmrEF and semi-quantitative patients are shown in Table [2](#Tab2){ref-type="table"}. Both overall prescription rates and ranges between centres did not differ in a clinically meaningful way from those in HFrEF patients. Also, in all LVEF groups, there was a wide range of prescribed dosages of HF medication percentages between centres (Suppl. Fig. 1, 2 and 3).

Discussion {#Sec7}
==========

From our outpatient HF registry in a representative number of centres in the Netherlands, we demonstrated that demography, HF characteristics and comorbidities in HFrEF patients widely varied between those centres. Also, the prescription rates and prescribed dosages of guideline-recommended HF medication varied significantly, both for HFrEF and HFmrEF patients. Those variations between hospitals could not be explained by differences in baseline characteristics of participating HF patients.

Overall, we found higher prescription rates of recommended HF medication than in previous registries, which may be related to the delivery of specialist outpatient HF care in the vast majority of patients \[[@CR10]\].

Variation in prescribed heart failure medication {#Sec8}
------------------------------------------------

Remarkably, a wide distribution of prescribed medication between centres was observed. Many factors may play a role both in suboptimal therapy in the HF patients and in substantial variations between centres. Previously we reported from CHECK-HF that lower rates of guideline-directed pharmacotherapy in HFrEF patients were associated with increasing age, but much less influenced by comorbidities \[[@CR10]\]. Recorded contraindications and intolerabilities did not explain the underuse of RAS inhibitors, beta blockers and MRA. Further analyses demonstrated that elderly heart failure patients with reduced ejection fraction (≥75 years) were prescribed significantly fewer beta blockers (77.8% vs 84.2%), RAS inhibitors (75.2% vs 89.7%), MRAs (50.6% vs 59.6%) and ivabradine (2.9% vs 9.3%), but significantly more diuretics (88.1% vs 72.6%) compared with patients aged less than 60 (*P* for all trends \<0.01) \[[@CR16]\]. In addition, the prescribed target dosages were significantly lower in elderly patients. Notably, patients with HFmrEF showed a similar trend in use of medication as in patients with HFrEF.

Also, recently reported data from the CHAMP-HF registry with 3,518 participating patients from 150 primary care and cardiology practices, demonstrated that lower medication utilisation or dose, was associated with older age, lower blood pressure, more severe functional class, renal insufficiency, and recent HF hospitalisation \[[@CR9]\].

Notably, only 40% of the total HFrEF cohort of the Swedish Heart Failure Registry (11,215 patients, 27% women; mean age 75 ± 11 years) received an MRA \[[@CR17]\]. Underuse of MRA was not related to hyperkalaemia, but it was, among other factors, related to impaired renal function (even moderately impaired), which is not a contraindication for MRA use. An explanation for the underuse of MRA might be the reluctance of prescribing an MRA to a vulnerable group of HF patients, already treated with an RAS inhibitor, beta blocker and in the majority of cases also a diuretic \[[@CR18], [@CR19]\]. Remarkably, age of patients in the present analysis had no impact on the differences in prescription of HF medication between centres.

Therefore, perceived polypharmacy, presence of comorbidities and overestimation of side-effects may influence use and dosing of evidence-based medication. In addition, patient preferences and family caregiver perceptions may influence therapeutic decisions \[[@CR20]\]. Furthermore, an analysis by the BIOSTAT-CHF study group suggested that women with HFrEF might need lower doses of RAS inhibitors and beta blockers than men, also adjusted for age \[[@CR21]\].

However, it is unclear why not only new medication, e.g. ivabradine and more recently sacubitril/valsartan, but also long-standing, established, disease-modifying therapies are not widely adopted nor fully prescribed. Therefore, it is important to gain detailed insights in reasons for not adopting recommended therapies both at a hospital level and at an individual patient level. Assessing information on real motivation of medical decisions and perceived barriers would contribute to effective improvement of HF care.

Importantly, suboptimal use of HF medication may have detrimental effects on clinical outcomes. Adherence to guideline-directed therapy of HFrEF, with prescription of at least 50% of the target dosage is associated with better outcome \[[@CR6], [@CR22]\], at least in younger patients with little comorbidities \[[@CR23]\].

Optimising heart failure management {#Sec9}
-----------------------------------

Although nonadherence to guideline-directed HF therapies is not fully understood, several practical recommendations to improve HF management can be made (Suppl. Table 8).

Obviously, being informed on performance of health care professionals involved in HF management, will contribute to improving delivery of care. Therefore, the CHECK-HF centres received individual feedback and in national meetings possible solutions to optimise HF care were shared. Furthermore, a nationwide, structured HF registry is being launched.

Acknowledging that HF care should be delivered seamless to patients, the Netherlands Society of Cardiology, started the CONNECT Heart Failure programme, in which concepts of integrated collaboration were translated towards detailed protocols by joint health care professionals in geographic regions \[[@CR24]\]. These collaborations also provide strategies for optimising diagnostic pathways and HF therapies, accompanied by educational activities for professional teams. The initiated national registry will provide information on the effectiveness of incorporating these strategies.

At a patient level, clinical judgment of the heart failure syndrome, management of comorbidities, in concert with optimally implemented disease-modifying therapies are of pivotal importance \[[@CR25]--[@CR27]\]. In addition, blood pressure, renal function and hyperkalaemia may limit up-titration of all recommended drugs \[[@CR28]\]. This may be even more complicated by the fact that the number of drug classes shown to improve outcome in HFrEF is increasing \[[@CR29]\]. Among potential solutions are start-low and go-slow dosing strategies, close monitoring of vital parameters and side-effects, the use of new potassium binders and angiotensin receptor/neprilysin inhibition. Critical appraisal and reduction of co-medication may also be beneficial. In addition, pharmacy care improves adherence to HF medications and quality of life, which was recently demonstrated by the PHARM-CHF investigators \[[@CR30]\].

In concert with dedicated efforts of professional HF teams, well-informed patients and family caregivers may empower their participation in medical decision-making and contributes to earlier access of new therapies \[[@CR5], [@CR24]\]. Informed treatment choices are of particular relevance in guidance of decisions during advanced and palliative stages of care.

Limitations and strenghts {#Sec10}
=========================

The CHECK-HF registry is a large-scale real-world registry of HF outpatient clinics in the Netherlands reflective of Western European countries. However, some limitations should be mentioned, such as the cross-sectional design limiting follow-up data on patient outcomes. Some missing data exists, which might influence results. Our registry included only patients seen in secondary, but not in primary care, which limits the generalisability of our findings to the primary care setting. Information on actual protocols of diagnostic workup and medical decision-making strategies in centres was not collected. Notably, the CHECK-HF inclusion period was from 2013 till end of 2016, in which the CONNECT programme for Heart failure regional care had been in the initial phase of implementation in regions. Therefore, we have not collected data on adoption of the CONNECT Heart Failure programme in the centres. Strengths of the study are the reflection of the true practice of large scale nationwide outpatient HF management with detailed information on medication prescription and dosage.

Conclusion {#Sec11}
==========

In this Dutch real-world registry of outpatient HF population, wide between-clinic ranges of demography, severity of heart failure and comorbidities of HF patients were observed. Also the prescription rates and prescribed dosages of guideline-recommended HF medication differed significantly, not fully explained by differences in the patient profiles. Thus, future research should lead to strategies to improve management of HF patients including reduction of practice variation.
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**4. Suppl. Table 4.** Prescription rates of HF medication according to ESC Guidelines 2012 versus 2016 per participating clinic (*n* = 34), only for symptomatic patients
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**5. Suppl. Table 5.** Prescription rates of HF medication according to ESC Guidelines 2012 versus 2016 per participating clinic (*n* = 34)
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**6. Suppl. Table 6.** Prescription rates of HF medication according to ESC Guidelines 2012 versus 2016 per participating clinic (*n* = 34)
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**7. Suppl. Table 7**. Univariable analysis of predictors of HF medical treatment of HFrEF patients (LVEF \<50%), Odds Ratios \[95% confidence intervals\]
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**8. Suppl. Table 8.** Practical recommendations for optimal use of guideline-directed heart failure therapies
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**9. Suppl. Fig. 1.**Prescription rates (%) and prescribed dosages (%) of HF medication in HFrEF patients (LVEF \<40%) per participating clinic (*n* = 34) (*The left panels* show the order of hospitals on the x‑axis based on the percentage of prescription rate of each drug. *The red bar* is the overall prescription rate (%) and *the green bars* are the prescription rates (%) in each clinic. The same order is shown in *the panels on the right*). (*HF* heart failure, *HFrEF* heart failure with reduced ejection fraction, *LVEF* left ventricular ejection fraction, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonists)
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**10. Suppl. Fig. 2**. Prescription rates (%) and prescribed dosages (%) of HF medication in HFmrEF patients (LVEF 40--49%) per participating clinic (*n* = 34) (*The left panels* show the order of hospitals on the x‑axis based on the percentage of prescription rate of each drug. *The red bar* is the overall prescription rate (%) and *the green bars* are the prescription rates (%) in each clinic. The same order is shown in *the panels on the right*). (*HF* heart failure, *HFmrEF* heart failure with mid-range ejection fraction, *LVEF* left ventricular ejection fraction, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonists)
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**11. Suppl. Fig. 3**. Prescription rates and prescribed dosages of HF medication in HF patients with semiquantitatively measured LV function per participating clinic (*n* = 27) (*The left panels* show the order of hospitals on the x‑axis based on the percentage of prescription rate of each drug. *The red bar* is the overall prescription rate (%) and *the green bars* are the prescription rates (%) in each clinic. The same order is shown in *the panels on the right*). (*HF* heart failure, *LV* left ventricular, *RAS* renin-angiotensin system, *MRA* mineralocorticoid receptor antagonists)
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